株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Millennium Pharmaceuticals, Inc. - 製品パイプライン分析

Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 251690
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
Millennium Pharmaceuticals, Inc. - 製品パイプライン分析 Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日: 2014年07月22日 ページ情報: 英文 96 Pages
概要

Millennium Pharmaceuticals, Inc.は、癌治療薬の研究開発及び商品化を担うバイオ製薬会社です。主力製品である Velcade (bortezomib) は、多発性骨髄腫と再発性マントル細胞リンパ腫の治療のために開発されました。同社製品には様々なタイプの癌をターゲットにした15種類以上の腫瘍治験化合物があります。

当レポートでは、Millennium Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Millennium Pharmaceuticals, Inc.の基本情報

Millennium Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Millennium Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Millennium Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Millennium Pharmaceuticals, Inc.:パイプライン製品の概況

Millennium Pharmaceuticals, Inc.

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 出願が却下された/取り下げられた製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Millennium Pharmaceuticals, Inc.:薬剤プロファイル

  • bortezomib
  • alisertib
  • brentuximab vedotin
  • ixazomib citrate
  • MLN-0128
  • MLN-2480
  • orteronel
  • MLN-0264
  • MLN-1117
  • MLN-7243
  • pevonedistat hydrochloride
  • TAK-659
  • TAK-733
  • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner

Millennium Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Millennium Pharmaceuticals, Inc.:最近のパイプライン動向

Millennium Pharmaceuticals, Inc.:休止中のプロジェクト

Millennium Pharmaceuticals, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • alisertib
    • betrixaban
    • bortezomib
    • HuL-2G7
    • orteronel
    • TAK-441
    • TAK-448
    • TAK-901
    • TAK-960
    • tandutinib

Millennium Pharmaceuticals, Inc.:企業発表

Millennium Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC05275CDB

Summary

Global Markets Direct's, 'Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Millennium Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Millennium Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Millennium Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Millennium Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Millennium Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Millennium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Millennium Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Millennium Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Millennium Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Millennium Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Millennium Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Millennium Pharmaceuticals, Inc. Snapshot
    • Millennium Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Millennium Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Millennium Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
    • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals, Inc. - Pipeline Products Glance
    • Millennium Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals, Inc. - Drug Profiles
    • bortezomib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-0128
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-2480
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orteronel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-0264
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-1117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-7243
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pevonedistat hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-659
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-733
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Millennium Pharmaceuticals, Inc. - Pipeline Analysis
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Target
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Millennium Pharmaceuticals, Inc. - Dormant Projects
  • Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alisertib
      • betrixaban
      • bortezomib
      • HuL-2G7
      • orteronel
      • TAK-441
      • TAK-448
      • TAK-901
      • TAK-960
      • tandutinib
  • Millennium Pharmaceuticals, Inc. - Company Statement
  • Millennium Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Millennium Pharmaceuticals, Inc., Key Information
  • Millennium Pharmaceuticals, Inc., Key Facts
  • Millennium Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Millennium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Millennium Pharmaceuticals, Inc. - Pre-Registration, 2014
  • Millennium Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014
  • Millennium Pharmaceuticals, Inc. - Phase III, 2014
  • Millennium Pharmaceuticals, Inc. - Phase II, 2014
  • Millennium Pharmaceuticals, Inc. - Phase I, 2014
  • Millennium Pharmaceuticals, Inc. - Preclinical, 2014
  • Millennium Pharmaceuticals, Inc. - Discovery, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Millennium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top